Fragile X syndrome

Randi J Hagerman, Elizabeth Berry-Kravis, Heather Cody Hazlett, Donald B. Bailey, Herve Moine, R. Frank Kooy, Flora Tassone, Ilse Gantois, Nahum Sonenberg, Jean Louis Mandel, Paul J Hagerman

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

Fragile X syndrome (FXS) is the leading inherited form of intellectual disability and autism spectrum disorder, and patients can present with severe behavioural alterations, including hyperactivity, impulsivity and anxiety, in addition to poor language development and seizures. FXS is a trinucleotide repeat disorder, in which >200 repeats of the CGG motif in FMR1 leads to silencing of the gene and the consequent loss of its product, fragile X mental retardation 1 protein (FMRP). FMRP has a central role in gene expression and regulates the translation of potentially hundreds of mRNAs, many of which are involved in the development and maintenance of neuronal synaptic connections. Indeed, disturbances in neuroplasticity is a key finding in FXS animal models, and an imbalance in inhibitory and excitatory neuronal circuits is believed to underlie many of the clinical manifestations of this disorder. Our knowledge of the proteins that are regulated by FMRP is rapidly growing, and this has led to the identification of multiple targets for therapeutic intervention, some of which have already moved into clinical trials or clinical practice.

Original languageEnglish (US)
Number of pages1
JournalNature reviews. Disease primers
Volume3
DOIs
StatePublished - Sep 29 2017
Externally publishedYes

Fingerprint

Fragile X Mental Retardation Protein
Fragile X Syndrome
Trinucleotide Repeats
Language Development
Neuronal Plasticity
Impulsive Behavior
Gene Silencing
Intellectual Disability
Seizures
Anxiety
Animal Models
Maintenance
Clinical Trials
Gene Expression
Messenger RNA
Proteins
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., ... Hagerman, P. J. (2017). Fragile X syndrome. Nature reviews. Disease primers, 3. https://doi.org/10.1038/nrdp.2017.65

Fragile X syndrome. / Hagerman, Randi J; Berry-Kravis, Elizabeth; Hazlett, Heather Cody; Bailey, Donald B.; Moine, Herve; Kooy, R. Frank; Tassone, Flora; Gantois, Ilse; Sonenberg, Nahum; Mandel, Jean Louis; Hagerman, Paul J.

In: Nature reviews. Disease primers, Vol. 3, 29.09.2017.

Research output: Contribution to journalReview article

Hagerman, RJ, Berry-Kravis, E, Hazlett, HC, Bailey, DB, Moine, H, Kooy, RF, Tassone, F, Gantois, I, Sonenberg, N, Mandel, JL & Hagerman, PJ 2017, 'Fragile X syndrome', Nature reviews. Disease primers, vol. 3. https://doi.org/10.1038/nrdp.2017.65
Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF et al. Fragile X syndrome. Nature reviews. Disease primers. 2017 Sep 29;3. https://doi.org/10.1038/nrdp.2017.65
Hagerman, Randi J ; Berry-Kravis, Elizabeth ; Hazlett, Heather Cody ; Bailey, Donald B. ; Moine, Herve ; Kooy, R. Frank ; Tassone, Flora ; Gantois, Ilse ; Sonenberg, Nahum ; Mandel, Jean Louis ; Hagerman, Paul J. / Fragile X syndrome. In: Nature reviews. Disease primers. 2017 ; Vol. 3.
@article{afa188599c7c44c68dc1dd5488c87a5a,
title = "Fragile X syndrome",
abstract = "Fragile X syndrome (FXS) is the leading inherited form of intellectual disability and autism spectrum disorder, and patients can present with severe behavioural alterations, including hyperactivity, impulsivity and anxiety, in addition to poor language development and seizures. FXS is a trinucleotide repeat disorder, in which >200 repeats of the CGG motif in FMR1 leads to silencing of the gene and the consequent loss of its product, fragile X mental retardation 1 protein (FMRP). FMRP has a central role in gene expression and regulates the translation of potentially hundreds of mRNAs, many of which are involved in the development and maintenance of neuronal synaptic connections. Indeed, disturbances in neuroplasticity is a key finding in FXS animal models, and an imbalance in inhibitory and excitatory neuronal circuits is believed to underlie many of the clinical manifestations of this disorder. Our knowledge of the proteins that are regulated by FMRP is rapidly growing, and this has led to the identification of multiple targets for therapeutic intervention, some of which have already moved into clinical trials or clinical practice.",
author = "Hagerman, {Randi J} and Elizabeth Berry-Kravis and Hazlett, {Heather Cody} and Bailey, {Donald B.} and Herve Moine and Kooy, {R. Frank} and Flora Tassone and Ilse Gantois and Nahum Sonenberg and Mandel, {Jean Louis} and Hagerman, {Paul J}",
year = "2017",
month = "9",
day = "29",
doi = "10.1038/nrdp.2017.65",
language = "English (US)",
volume = "3",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Fragile X syndrome

AU - Hagerman, Randi J

AU - Berry-Kravis, Elizabeth

AU - Hazlett, Heather Cody

AU - Bailey, Donald B.

AU - Moine, Herve

AU - Kooy, R. Frank

AU - Tassone, Flora

AU - Gantois, Ilse

AU - Sonenberg, Nahum

AU - Mandel, Jean Louis

AU - Hagerman, Paul J

PY - 2017/9/29

Y1 - 2017/9/29

N2 - Fragile X syndrome (FXS) is the leading inherited form of intellectual disability and autism spectrum disorder, and patients can present with severe behavioural alterations, including hyperactivity, impulsivity and anxiety, in addition to poor language development and seizures. FXS is a trinucleotide repeat disorder, in which >200 repeats of the CGG motif in FMR1 leads to silencing of the gene and the consequent loss of its product, fragile X mental retardation 1 protein (FMRP). FMRP has a central role in gene expression and regulates the translation of potentially hundreds of mRNAs, many of which are involved in the development and maintenance of neuronal synaptic connections. Indeed, disturbances in neuroplasticity is a key finding in FXS animal models, and an imbalance in inhibitory and excitatory neuronal circuits is believed to underlie many of the clinical manifestations of this disorder. Our knowledge of the proteins that are regulated by FMRP is rapidly growing, and this has led to the identification of multiple targets for therapeutic intervention, some of which have already moved into clinical trials or clinical practice.

AB - Fragile X syndrome (FXS) is the leading inherited form of intellectual disability and autism spectrum disorder, and patients can present with severe behavioural alterations, including hyperactivity, impulsivity and anxiety, in addition to poor language development and seizures. FXS is a trinucleotide repeat disorder, in which >200 repeats of the CGG motif in FMR1 leads to silencing of the gene and the consequent loss of its product, fragile X mental retardation 1 protein (FMRP). FMRP has a central role in gene expression and regulates the translation of potentially hundreds of mRNAs, many of which are involved in the development and maintenance of neuronal synaptic connections. Indeed, disturbances in neuroplasticity is a key finding in FXS animal models, and an imbalance in inhibitory and excitatory neuronal circuits is believed to underlie many of the clinical manifestations of this disorder. Our knowledge of the proteins that are regulated by FMRP is rapidly growing, and this has led to the identification of multiple targets for therapeutic intervention, some of which have already moved into clinical trials or clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85044643762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044643762&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2017.65

DO - 10.1038/nrdp.2017.65

M3 - Review article

C2 - 28960184

AN - SCOPUS:85044643762

VL - 3

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

ER -